Niagen Bioscience
Natalia Pedrosa is the Chief Financial Officer at ChromaDex since June 2023, a bioscience company focused on healthy aging and the study of nicotinamide adenine dinucleotide (NAD+). Previously, Natalia held various roles at Mattel, Inc. from October 2013 to May 2023, including Director of Corporate Financial Planning & Analysis, where responsibilities included leading the annual planning process for balance sheet and cash flow, and introducing processes aligned with growth objectives. Additional roles at Mattel included Senior Manager of Corporate Financial Planning & Analysis and Senior Manager of Investor Relations, where significant achievements included managing communication with the financial community during key corporate events. Prior experience includes serving as a Results Analyst at Capital Guardian Trust Company from June 2008 to September 2013. Natalia earned an MBA in Finance and Management from USC Marshall School of Business and a Bachelor's Degree in Economics from Sun Yat-sen University - Lingnan (University) College.
This person is not in any offices
Niagen Bioscience
Niagen Bioscience (NASDAQ:NAGE), founded in 1999 and formerly known as ChromaDex, is the global authority on nicotinamide adenine dinucleotide (NAD+), dedicated to advancing healthy-aging science. Our world-renowned scientists collaborate with independent investigators from leading universities and research institutions worldwide to explore the full potential of NAD+, a vital coenzyme found in every cell that declines with age and everyday stressors. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, Niagen Bioscience is the innovator behind Niagen® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. Our ingredient is backed by 35+ human clinical trials and 400+ peer-reviewed studies, making it one of the world's most extensively researched and validated NAD+ precursors. We offer two distinct product lines: Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States*, clinically proven to increase NAD+ levels and help people transform the way they age (available at www.truniagen.com) Niagen® Plus, our premium pharmaceutical-grade NAD+ therapy featuring Niagen™ IV and injectables, available exclusively at clinics with a prescription (www.niagenplus.com) Our robust patent portfolio protects NR and other NAD+ precursors. As pioneers in NAD+ technology, we continue to demonstrate our commitment to excellence, innovation, and integrity through our two California locations (Tustin and Westwood) and our premier research Laboratory & Innovation Center in Longmont, CO. Visit www.niagenbioscience.com for press releases, news, and financial information. Interested in joining our team? Explore career opportunities at https://jobs.lever.co/niagenbioscience +Based on the top selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace. (1/1/24-12/31/24)